Pushkal Garg, CMO & EVP Development & Med Affairs at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 4,204 shares at $243.13 ($1.0M) on 2025-03-03, disclosed to the SEC on 2025-03-05.
Scheduled sale ($1.0M) by CMO & EVP Development & Med Affairs under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $242.37 | 213 | $52K | 5.1% |
| 2 | $242.37 | 213 | $52K | 5.1% |
| 3 | $243.13 | 583 | $142K | 13.9% |
| 4 | $243.13 | 583 | $142K | 13.9% |
| 5 | $243.36 | 235 | $57K | 5.6% |
| 6 | $243.36 | 235 |
| $57K |
| 5.6% |
| 7 | $244.41 | 158 | $39K | 3.8% |
| 8 | $244.43 | 273 | $67K | 6.5% |
| 9 | $244.43 | 273 | $67K | 6.5% |
| 10 | $245.26 | 116 | $28K | 2.8% |
| 11 | $245.53 | 117 | $29K | 2.8% |
| 12 | $246.18 | 48 | $12K | 1.2% |
| 13 | $247.35 | 5 | $1K | 0.1% |
| 14 | $248.36 | 1 | $248 | 0.0% |
| 15 | $239.25 | 147 | $35K | 3.4% |
| 16 | $240.92 | 343 | $83K | 8.1% |
| 17 | $240.92 | 343 | $83K | 8.1% |
| 18 | $241.60 | 198 | $48K | 4.7% |
| 19 | $242.70 | 120 | $29K | 2.9% |
| Total | $242.88 avg | 4,204 | $1.0M | 100% |
| Filing → |
| ALNY | SELL | 2026-03-02 | $1.5M | — | Filing → |
| ALNY | SELL | 2026-02-17 | $695K | — | Filing → |
| ALNY | SELL | 2026-01-14 | $548K | — | Filing → |